Home Alzheimer’s Disease FDA Approves Nivolumab Plus Ipilimumab with Chemotherapy for NSCLC

FDA Approves Nivolumab Plus Ipilimumab with Chemotherapy for NSCLC

The FDA has approved the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) given with 2 cycles of platinum-doublet chemotherapy as a first-line treatment for adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations, according to Bristol Myers Squibb, the developer of the agents.  

The therapy has been approved for patients with squamous or non-squamous disease, regardless of PD-L1 expression. 

Previously on May 15, the FDA approved the combination as a first-line treatment for certain patients with metastatic NSCLC whose tumors express PD-L1 ≥ 1% as determined by an FDA-approved test. 

“Non-small cell lung cancer is a complex disease that requires multiple treatment options to address the needs of different patient populations,” Adam Lenkowsky, general manager and head of Oncology, Immunology, and…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments